Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for the Prevention of Chronic Migraine
NCT07018713Phase 3Active, not recruiting
- Sponsor
- Merz
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of incobotulinumtoxinA in chronic migraine, sponsored by Merz. Started Aug 2025; status: active, not recruiting.
02
Drugs
incobotulinumtoxinA
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT07018713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018713.